Telescope Innovations Corp. (CSE: TELI) (OTCQB: TELIF) (FSE: J4U) has announced that members of its leadership team will attend the Planet MicroCap Toronto Investment Conference on October 27, 28, and 29 at the Arcadian Loft, 401 Bay Street. The Vancouver-based Physical AI developer will hold one-on-one meetings with investors, analysts, and industry participants. The appearance gives the company a platform to highlight three Self-Driving Laboratory deployments completed during its 2026 fiscal year and its flagship DirectInject-LC™ technology.

Key Points

  • Telescope Innovations Corp. (CSE: TELI) develops Physical AI systems, including Self-Driving Laboratories, for the pharmaceutical and high-value chemical industries.
  • CEO Henry Dubina will present on Wednesday, October 28 from 4:00–4:30 PM and conduct one-on-one meetings on Thursday, October 29.
  • The company completed three SDL engagements in fiscal 2026: deployments at KPBMA in Korea, at Pfizer under a Master Collaborative Research Agreement, and with a major global pharmaceutical company for European operations.
  • Investors may be watching for any commentary on SDL pipeline expansion and commercial momentum for DirectInject-LC™.

Telescope's SDL Milestones Ahead of Toronto Investor Meetings

Telescope enters the Toronto conference with three Self-Driving Lab deployments confirmed during its 2026 fiscal year. The first was Korea's inaugural pharmaceutical SDL, installed at the Korea Pharmaceutical and Biopharma Manufacturer's Association in December 2025. A second SDL followed at Pfizer in February 2026 under a Master Collaborative Research Agreement. A third SDL was subsequently signed with a major global pharmaceutical company for its European operations in June 2026. These engagements collectively span North America, Europe, and Asia, reflecting the company's stated international growth strategy.

CEO Presentation and One-on-One Meetings at Arcadian Loft

Chief Executive Officer Henry Dubina is scheduled to host Telescope's formal presentation on Wednesday, October 28 from 4:00 to 4:30 PM, where he will take questions from conference attendees. One-on-one meetings with investors and analysts are planned for Thursday, October 29. The release states that management will be available to discuss SDL deployments, the DirectInject-LC™ reaction sampling system, and the company's broader growth strategy. The company did not disclose specific investor targets or the number of meetings scheduled.

DirectInject-LC™ and Physical AI Positioning for Pharma Clients

Telescope describes itself as a developer of Physical AI systems that combine robotics, real-time analytics, and artificial intelligence to conduct chemistry experiments faster and more consistently than manual methods. Its DirectInject-LC™ system is characterised in the release as the company's flagship product for reaction sampling. Clients cited in the company's corporate profile include biopharmaceutical, specialty chemical, and advanced materials companies. Investors may be watching how the company articulates commercial differentiation for DirectInject-LC™ relative to SDL services at the Toronto event.